{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:58:07Z","timestamp":1788933487312,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821520"],"award-info":[{"award-number":["821520"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open access funding provided by Universit\u00e9 de Toulouse"},{"DOI":"10.13039\/501100004718","name":"Universit\u00e9 de Toulouse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004718","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40264-025-01565-2","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T14:26:24Z","timestamp":1749824784000},"page":"1189-1204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying Maternal Conditions Leading to Gabapentinoid Prescriptions in Pregnancy Using Electronic Health Records from Six European Countries: A Contribution from the IMI ConcePTION Project"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-100X","authenticated-orcid":false,"given":"Anna-Belle","family":"Beau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"B\u00e9n\u00e9vent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beslay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Moisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ballardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Barrachina-Bonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Cavero-Carbonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Coldea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Garc\u00eda-Villodre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Geldhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Gini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Gissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit K.","family":"Leinonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Manfrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visa","family":"Martikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera R.","family":"Mitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan K.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Neville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig","family":"Nordeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Damase-Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"1565_CR1","doi-asserted-by":"publisher","unstructured":"Paoletti O, RosaMGini. IMI-ConcePTION\/DP1-Neuropathic-pain: DP1 ALGO final [Internet]. Zenodo; 2025. https:\/\/doi.org\/10.5281\/zenodo.14746934.","DOI":"10.5281\/zenodo.14746934"},{"key":"1565_CR2","doi-asserted-by":"publisher","unstructured":"Beau A-B, Damase-Michel C, Mo J, Moisset X. Final study protocols for demonstration projects submitted to EU PAS register (D1.3) [Internet]. Zenodo; 2022. https:\/\/doi.org\/10.5281\/zenodo.7476130.","DOI":"10.5281\/zenodo.7476130"},{"key":"1565_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.07.005","volume":"87","author":"C Johannessen Landmark","year":"2009","unstructured":"Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders\u2014a population-based study of prescriptions. Epilepsy Res. 2009;87:31\u20139.","journal-title":"Epilepsy Res"},{"key":"1565_CR4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/pds.2195","volume":"21","author":"H Wallach Kildemoes","year":"2012","unstructured":"Wallach Kildemoes H, Hendriksen C, Andersen M. Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemiol Drug Saf. 2012;21:1027\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1565_CR5","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/pds.4881","volume":"28","author":"R Charlton","year":"2019","unstructured":"Charlton R, Damase-Michel C, Hurault-Delarue C, Gini R, Loane M, Pierini A, et al. Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016. Pharmacoepidemiol Drug Saf. 2019;28:1519\u201328.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1565_CR6","unstructured":"Brunton LL, Knollmann BC. Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, 14th Edition [Internet]. New York: McGraw-Hill Education; 2023 [cited 2024 Dec 6]. https:\/\/accessmedicine.mhmedical.com\/content.aspx?aid=1198876907."},{"key":"1565_CR7","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/pds.3847","volume":"24","author":"R Charlton","year":"2015","unstructured":"Charlton R, Garne E, Wang H, Klungs\u00f8yr K, Jordan S, Neville A, et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions. Pharmacoepidemiol Drug Saf. 2015;24:1144\u201354.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1565_CR8","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.2018.12358","volume":"320","author":"F Montastruc","year":"2018","unstructured":"Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993\u20132017. JAMA. 2018;320:2149\u201351.","journal-title":"JAMA"},{"key":"1565_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021535","volume":"9","author":"A Viniol","year":"2019","unstructured":"Viniol A, Ploner T, Hickstein L, Haasenritter J, Klein KM, Walker J, et al. Prescribing practice of pregabalin\/gabapentin in pain therapy: an evaluation of German claim data. BMJ Open. 2019;9: e021535.","journal-title":"BMJ Open"},{"key":"1565_CR10","doi-asserted-by":"crossref","unstructured":"Andrea L Schaffer, Doreen Busingye, Kendal Chidwick, Jonathan Brett, Suzanne Blogg. Pregabalin prescribing patterns in Australian general practice, 2012\u20132018: a cross-sectional study. BJGP Open. 2021;5:bjgpopen20X101120.","DOI":"10.3399\/bjgpopen20X101120"},{"key":"1565_CR11","doi-asserted-by":"crossref","unstructured":"Huang LL, Wright JA, Fischer KM, Croghan IT, Nanda S, Schroeder DR, et al. Gabapentinoid prescribing practices at a large academic medical center. mcp:iqo. 2023;7:58\u201368.","DOI":"10.1016\/j.mayocpiqo.2022.12.002"},{"key":"1565_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/pds.5035","volume":"29","author":"JM Cohen","year":"2020","unstructured":"Cohen JM, Cesta CE, Furu K, Einarsd\u00f3ttir K, Gissler M, Havard A, et al. Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006\u20132016: a study in the five Nordic countries, United States, and Australia. Pharmacoepidemiol Drug Saf. 2020;29:913\u201322.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1565_CR13","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/pds.4897","volume":"28","author":"C Hurault-Delarue","year":"2019","unstructured":"Hurault-Delarue C, Morris JK, Charlton R, Gini R, Loane M, Pierini A, et al. Prescription of antiepileptic medicines including valproate in pregnant women: a study in three European countries. Pharmacoepidemiol Drug Saf. 2019;28:1510\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1565_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40264-023-01307-2","volume":"46","author":"E Dudukina","year":"2023","unstructured":"Dudukina E, Sz\u00e9pligeti SK, Karlsson P, Asomaning K, Daltveit AK, Hakkarainen K, et al. Prenatal exposure to pregabalin, birth outcomes and neurodevelopment\u2014a population-based cohort study in four Nordic countries. Drug Saf. 2023;46:661\u201375.","journal-title":"Drug Saf"},{"key":"1565_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007696","volume":"93","author":"P-O Bloti\u00e8re","year":"2019","unstructured":"Bloti\u00e8re P-O, Raguideau F, Weill A, Elefant E, Perthus I, Goulet V, et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019;93: e167.","journal-title":"Neurology"},{"key":"1565_CR16","doi-asserted-by":"publisher","first-page":"17362","DOI":"10.1038\/s41598-020-74409-x","volume":"10","author":"J Coste","year":"2020","unstructured":"Coste J, Blotiere P-O, Miranda S, Mikaeloff Y, Peyre H, Ramus F, et al. Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep. 2020;10:17362.","journal-title":"Sci Rep"},{"key":"1565_CR17","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1212\/WNL.0000000000003959","volume":"88","author":"E Patorno","year":"2017","unstructured":"Patorno E, Bateman BT, Huybrechts KF, MacDonald SC, Cohen JM, Desai RJ, et al. Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology. 2017;88:2020\u20135.","journal-title":"Neurology"},{"key":"1565_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/jnnp-2023-333149","volume":"95","author":"H Forbes","year":"2024","unstructured":"Forbes H, Madley-Dowd P, Ahlqvist V, Campbell J, Davies NM, Liebling R, et al. First-trimester use of antiseizure medications and the risk of miscarriage: a population-based cohort study. J Neurol Neurosurg Psychiatry. 2024;95:693\u2013703.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1565_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003322","volume":"17","author":"E Patorno","year":"2020","unstructured":"Patorno E, Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Med. 2020;17: e1003322.","journal-title":"PLoS Med"},{"key":"1565_CR20","doi-asserted-by":"crossref","unstructured":"Desrochers B, Lavu A, Valencia E, Vaccaro C, Peymani P, Eltonsy S. Risks of congenital malformations and neonatal intensive care unit admissions with gabapentin use in pregnancy: a cohort study and scoping review with meta-analysis. Paediatr Perinat Epidemiol. 2024;","DOI":"10.1111\/ppe.13086"},{"key":"1565_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100849","volume":"38","author":"J Christensen","year":"2024","unstructured":"Christensen J, Zoega H, Leinonen MK, Gilhus NE, Gissler M, Igland J, et al. Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. Lancet Reg Health Eur. 2024;38: 100849.","journal-title":"Lancet Reg Health Eur."},{"key":"1565_CR22","unstructured":"UK Medicines and Healthcare products Regulatory Agency. MHRA\/CHM advice: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review (January 2021) Drug Safety Update 2022 [Internet]. 2022 [cited 2024 Jul 19]. https:\/\/www.gov.uk\/drug-safety-update\/pregabalin-lyrica-findings-of-safety-study-on-risks-during-pregnancy."},{"key":"1565_CR23","unstructured":"BNF [Internet]. NICE; [cited 2024 Jun 26]. https:\/\/bnf.nice.org.uk\/drugs\/gabapentin\/."},{"key":"1565_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cpt.2476","volume":"111","author":"NH Thurin","year":"2022","unstructured":"Thurin NH, Pajouheshnia R, Roberto G, Dodd C, Hyeraci G, Bartolini C, et al. From inception to ConcePTION: genesis of a network to support better monitoring and communication of medication safety during pregnancy and breastfeeding. Clin Pharmacol Ther. 2022;111:321\u201331.","journal-title":"Clin Pharmacol Ther"},{"key":"1565_CR25","doi-asserted-by":"publisher","unstructured":"Gini R. Report with publications on results of component algorithms (D7.16) [Internet]. Zenodo; 2024. https:\/\/doi.org\/10.5281\/zenodo.13860418.","DOI":"10.5281\/zenodo.13860418"},{"key":"1565_CR26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/pds.4556","volume":"27","author":"P-O Bloti\u00e8re","year":"2018","unstructured":"Bloti\u00e8re P-O, Weill A, Dalichampt M, Billionnet C, Mezzarobba M, Raguideau F, et al. Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: an application to antiepileptic drug use in 4.9 million pregnant women in France. Pharmacoepidemiol Drug Saf. 2018;27:763\u201370.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1565_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214180","volume":"14","author":"AV Margulis","year":"2019","unstructured":"Margulis AV, Hernandez-Diaz S, McElrath T, Rothman KJ, Plana E, Almqvist C, et al. Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. PLoS ONE. 2019;14: e0214180.","journal-title":"PLoS ONE"},{"key":"1565_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","volume":"79","author":"M-H Bj\u00f8rk","year":"2022","unstructured":"Bj\u00f8rk M-H, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K, et al. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol. 2022;79:672\u201381.","journal-title":"JAMA Neurol"},{"key":"1565_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bja.2020.05.017","volume":"125","author":"N Torrance","year":"2020","unstructured":"Torrance N, Veluchamy A, Zhou Y, Fletcher EH, Moir E, Hebert HL, et al. Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland. Br J Anaesth. 2020;125:159\u201367.","journal-title":"Br J Anaesth"},{"key":"1565_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","volume":"77","author":"KE Evoy","year":"2017","unstructured":"Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77:403\u201326.","journal-title":"Drugs"},{"key":"1565_CR31","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","volume":"30","author":"S Chiappini","year":"2016","unstructured":"Chiappini S, Schifano F. A Decade of gabapentinoid misuse: an analysis of the European medicines agency\u2019s \u201csuspected adverse drug reactions\u201d database. CNS Drugs. 2016;30:647\u201354.","journal-title":"CNS Drugs"},{"key":"1565_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fpsyt.2021.639780","volume":"12","author":"M Tambon","year":"2021","unstructured":"Tambon M, Pont\u00e9 C, Jouanjus E, Fouilh\u00e9 N, Micallef J, Lapeyre-Mestre M, et al. Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance. Front Psychiatry. 2021;12:37.","journal-title":"Front Psychiatry"},{"key":"1565_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/ijcp.12182","volume":"68","author":"B Wettermark","year":"2014","unstructured":"Wettermark B, Brandt L, Kieler H, Bod\u00e9n R. Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract. 2014;68:104\u201310.","journal-title":"Int J Clin Pract"},{"key":"1565_CR34","doi-asserted-by":"crossref","unstructured":"Haukka J. Finnish health and social welfare registers in epidemiological research. Nor J Epidemiol [Internet]. 2009 [cited 2024 Jul 25];14. https:\/\/www.ntnu.no\/ojs\/index.php\/norepid\/article\/view\/284.","DOI":"10.5324\/nje.v14i1.284"},{"key":"1565_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1403494812456637","volume":"40","author":"R Sund","year":"2012","unstructured":"Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J Public Health. 2012;40:505\u201315.","journal-title":"Scand J Public Health."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01565-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01565-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01565-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:03:25Z","timestamp":1760209405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01565-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1565"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01565-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"18 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e9 de Toulouse. The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 821520. This Joint Undertaking receives support from the European Union\u2019s Horizon 2020 research and innovation program and EFPIA. The research leading to these results was conducted as part of the ConcePTION consortium. This paper only reflects the personal views of the stated authors. Open access funding was enabled by Toulouse University Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AG is an employee of Janssen Biologics B.V. and owns stock\/stock options in Johnson & Johnson, of which Janssen is a subsidiary. XM has received financial support from Allergan-Abbvie, Amgen-Horizon, Aptyspharma, Biogen, BMS, Gr\u00fcnenthal, Lilly, Lundbeck, Teva, Merck-Serono, Novartis, Orion, Pfizer, Roche, Sanofi-Genzyme, and Sun Pharma and non-financial support from Dr Reddy\u2019s and SOS Oxyg\u00e8ne not related to the submitted work. JM is an employee of Pfizer Inc. and owns stock\/stock options of Pfizer Inc. All other co-authors have no competing interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Finland: Ethical approval is not required for register-based studies. The Institutional Review Board at the Finnish Institute for Health and Welfare approved the study and waived the requirement for obtaining informed consent for the secondary use of health administrative data from study participants (THL\/543\/6.02.00\/2021). Data were handled and stored in accordance with the General Data Protection Regulation. France: The EFEMERIS cohort was approved by the French Data Protection Authority on 7 April 2005 (authorization number 05-1140). This study was performed on anonymized patient data. The women included in the EFEMERIS database were informed of their inclusion and of the potential use of their anonymized data for research purposes. They could oppose the use of their data at any time. The women included in the EFEMERIS database know that their collected and anonymized data can be used for medical research purposes and can thus be published. The study was approved by the EFEMERIS steering group. Data were handled and stored in accordance with the General Data Protection Regulation. Italy: The study was approved by the local ethical committee (approval number 593\/2023\/Oss\/UniFe). Data were handled and stored in accordance with the General Data Protection Regulation and in agreement with the Authority for Healthcare and Welfare, Emilia Romagna Regional Health Service, Bologna, Italy. Norway: The study was approved by the Regional Committee for Research Ethics in South-East Norway (approval number 85224) and by the Data Protection Officer at the University of Oslo (approval number 519858). Data were handled and stored in accordance with the General Data Protection Regulation. Spain (Valencian region): The study (code: IMI-IMN-2019-01) was classified as an Observational Post-authorization Study \u201cOther designs\u201d (EPA-OD) by the Spanish Medicines Agency (AEMPS), available at:  and approved by the Arnau de Vilanova Hospital\u2019s Clinical Research Ethics Committee on 29 th January 2020, according to the Spanish regulations (approval number 1\/2020). At a regional level following the national Personal Data Protection and guaranteeing digital rights (Law 3\/2018), the study was approved by the Commission of the Regional Government (PROSIGA), which has the right to give RDRU Fisabio authorization to process the data (references: SD2556; SD2577; SD2578; SD2579; SD2580; SD2581; SD2582). Wales: This study uses anonymized data held in the Secure Anonymised Information Linkage (SAIL) Databank. The SAIL Databank independent Information Governance Review Panel (IGRP) approved the study as part of project 0823, on 16 th October 2020.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As the data were anonymized, informed consent was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All code lists and scripts are available from the Zenodo repository [].","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The study was primarily conceived and designed by ABB and CDM. All authors reviewed and provided input on the study protocol. All authors reviewed the statistical analysis plan, assessed the feasibility of statistical analyses against the local data, and provided input for data source-specific tailoring. OP translated the statistical analysis plan, primarily written by ABB, into analysis script. All authors read and approved the final version. Finland: ML applied for the study approval and obtained the Finnish data in this study. VM and ML were responsible for the mapping of the Finnish data onto the ConcePTION CDM. VM was responsible for data curation, running scripts on the Finnish data and debugging. ML and MG contributed to data interpretation and benchmarking of the Finnish data in the study. ML reviewed the aggregated Finnish results and approved their upload to the DRE (safe server at UMC). France: CDM applied for the study approval and obtained the French data in this study. CDM and ABB were responsible for the mapping of the French data onto the ConcePTION CDM. ABB was responsible for data curation, running scripts on the French data and debugging. CDM, ABB, MB, JB contributed to data interpretation and benchmarking of the French data in the study. ABB reviewed the aggregated French results and approved their upload to the DRE (safe server at UMC). Spain (Valencian region): CCC obtained all required approvals\u2014the Spanish Medicines Agency (AEMPS) classification and the Clinical Research Ethics Committee approval, and applied to the Regional Commission (PROSIGA) for the study data. LGV contributed to the reception and adequacy of the data format. LBB developed the mapping to the ConcePTION Common Data Model and executed the analysis scripts. During the script execution, LBB and CCC implemented the data quality assessment according to the study methodology and managed some issues during the process. LGV, CCC, and LBB contributed to data interpretation and the benchmarking of the Valencian region data and approved their upload to the DRE (safe server at UMC). CCC safeguarded custody of the local data into the institutional server. Wales: SJ applied for the study data and obtained all required approvals for the Wales data in this study. AC ran and cleaned the scripts. SJ curated and interpreted the data, benchmarked to published data, and approved uploading of aggregated data. Italy: EB and AN applied for the study data and obtained all required approvals for the Italian data in this study. AP was responsible for the mapping of the Italian data onto the ConcePTION CDM. MM was responsible for data curation, running scripts on the Italian data and debugging. AP and MM contributed to data interpretation and benchmarking of the Italian data in the study. MM reviewed the aggregated Italian results and approved their upload to the DRE (safe server at UMC). Norway: HN applied for the study data and obtained all required approvals for the Norwegian data in this study. HN was responsible for and HM and VRM contributed to data curation for the mapping of the Norwegian data onto the ConcePTION CDM. HN and VRM contributed to data interpretation and benchmarking of the Norwegian data in the study, and HN reviewed the aggregated Norwegian data and approved their upload to the DRE (safe server at UMC). Follow-up of data access providers and data analysis of aggregated data on the DRE was performed by ABB. The first draft of the manuscript was written by ABB and all authors commented on the previous versions of the manuscript. All authors contributed to the interpretation, discussed the results and approved the\u00a0final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"All relevant data are within the paper and its supporting information files. Authors may not share the study data due to regulations, which restrict access and distribution to those with ethical and legal permission to use the data. The study material is available to other researchers upon an application to relevant register holders. The study protocol was registered in the EUPAS Registry (EUPAS43385) and is available from the Zenodo repository []. All code lists and scripts are available from the Zenodo repository [].","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}